EPS for Coherus BioSciences, Inc. (CHRS) Expected At $-0.90

March 11, 2018 - By Henry Gaston

 EPS for Coherus BioSciences, Inc. (CHRS) Expected At $ 0.90
Investors sentiment decreased to 1.07 in 2017 Q3. Its down 1.02, from 2.09 in 2017Q2. It worsened, as 21 investors sold Coherus BioSciences, Inc. shares while 23 reduced holdings. 9 funds opened positions while 38 raised stakes. 46.59 million shares or 17.08% more from 39.79 million shares in 2017Q2 were reported.
Parallax Volatility Advisers Ltd Partnership holds 0% or 1,021 shares in its portfolio. California-based Schwab Charles Invest Mngmt has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). 594,021 are held by Brown Advisory. Us Fincl Bank De has 0% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS). Axa invested 0.02% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Highbridge Cap Mngmt Limited Liability Corp reported 33,906 shares. Sg Americas Ltd holds 11,705 shares or 0% of its portfolio. 6.28M were reported by Wellington Gru Ltd Liability Partnership. 98,012 were accumulated by Kennedy. Morgan Stanley, a New York-based fund reported 56,601 shares. 30,680 are held by Manufacturers Life Com The. Knott David M owns 34,320 shares or 0.2% of their US portfolio. Royal Bankshares Of Canada holds 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS) or 7,122 shares. State Board Of Administration Of Florida Retirement accumulated 0% or 17,763 shares. Citigroup accumulated 0% or 29,071 shares.

Analysts expect Coherus BioSciences, Inc. (NASDAQ:CHRS) to report $-0.90 EPS on March, 12.They anticipate $0.81 EPS change or 47.37 % from last quarter’s $-1.71 EPS. After having $-1.09 EPS previously, Coherus BioSciences, Inc.’s analysts see -17.43 % EPS growth. The stock increased 30.22% or $2.75 during the last trading session, reaching $11.85. About 6.05M shares traded or 722.84% up from the average. Coherus BioSciences, Inc. (NASDAQ:CHRS) has risen 17.62% since March 11, 2017 and is uptrending. It has outperformed by 0.92% the S&P500.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

Among 10 analysts covering Coherus Biosciences (NASDAQ:CHRS), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Coherus Biosciences had 20 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by Credit Suisse on Wednesday, September 27 with “Buy”. The stock has “Buy” rating by Maxim Group on Monday, June 12. Barclays Capital initiated Coherus BioSciences, Inc. (NASDAQ:CHRS) rating on Monday, November 23. Barclays Capital has “Overweight” rating and $46 target. Citigroup maintained the shares of CHRS in report on Friday, March 9 with “Buy” rating. Citigroup initiated Coherus BioSciences, Inc. (NASDAQ:CHRS) on Wednesday, July 27 with “Buy” rating. The rating was maintained by Cowen & Co on Monday, June 12 with “Buy”. Robert W. Baird maintained the shares of CHRS in report on Thursday, September 7 with “Buy” rating. Zacks upgraded the shares of CHRS in report on Thursday, September 3 to “Hold” rating. The stock of Coherus BioSciences, Inc. (NASDAQ:CHRS) has “Outperform” rating given on Wednesday, October 19 by Robert W. Baird. As per Friday, March 9, the company rating was maintained by Maxim Group.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $709.11 million. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

More recent Coherus BioSciences, Inc. (NASDAQ:CHRS) news were published by: Globenewswire.com which released: “Coherus BioSciences to Report Fourth Quarter and Full Year 2017 Financial …” on February 27, 2018. Also Fool.com published the news titled: “Why Coherus Biosciences Is Skyrocketing Today” on March 09, 2018. Stockhouse.com‘s news article titled: “Coherus BioSciences, Inc. to Host Earnings Call” with publication date: March 08, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: